查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1474872

鲍氏不动桿菌桿菌治疗药物市场规模、份额、趋势分析报告：依药物类别、给药途径、地区、细分市场预测，2024-2030年

Acinetobacter Pneumonia Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Xacduro, Polymyxins, Cephalosporins, Carbapenems), By Route Of Administration (Oral, Parenteral), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

鲍氏不动桿菌肺炎治疗药物市场成长与趋势：

根据Grand View Research, Inc.最新报告，预计到2030年，全球鲍氏不动桿菌肺炎治疗市场规模将达47,096万美元，2024年至2030年复合年增长率为6.70%。

有几个因素正在推动市场成长，包括不鲍氏不动桿菌感染疾病的高发生率、抗生素抗药性的上升、广泛的研究和开发、有利的政府倡议和资金以及抗药性的上升。鲍曼不动桿菌是引起住院病人医院感染的主要病原菌。这种病原体会导致人工呼吸器相关性肺炎和血流感染。据报道，该菌株具有多重抗药性，且传播速度极快。

这种生物体的治疗很困难，并且由于鲍曼不动桿菌的多重抗药性而受到阻碍。联合治疗是此类感染疾病最常使用的治疗方法。治疗鲍氏不动桿菌肺炎的第一线药物包括B-内酰胺类抗生素、头孢菌素类抗生素、碳青霉烯类抗生素、Fluoroquinolones抗生素、舒巴坦类抗生素、磺胺类药物抗生素等。根据严重程度，这些药物可以用作单一药物或联合治疗的一部分。如果第一线药物无效，则给予二线抗生素，如Aminoglycosides、多粘菌素类、四环霉素、Glycylcycline。这些药物因其副作用而被视为二线药物。

鲍氏不动桿菌肺炎治疗药物市场报告亮点

  • 2023 年，头孢菌素类药物类别占据最大收益占有率。头孢他啶用作第一线药物，头孢地罗用作二线药物。
  • 此外，在舒巴坦领域，新推出的 Zakuduro 预计在预测期内将以显着的复合年增长率成长。
  • 根据给药途径，注射给药领域在 2023 年占据了最大的收益占有率。透过静脉注射快速直接输送抗生素可确保快速吸收和有效性，使其成为治疗严重感染疾病的首选方法。
  • Zacduro（注射舒巴坦；注射杜洛巴坦）、多粘菌素（粘菌素）、碳青霉烯类和Aminoglycosides是一些用于治疗不鲍氏不动桿菌肺炎的胃肠外给药药物。
  • 2023年，北美地区占37.31%。这是由于先进的医疗基础设施、高度的意识和广泛的临床试验研究活动。
  • 该地区鲍氏不动桿菌肺炎盛行率较高，疾病诊治意识较高。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章鲍氏不动桿菌肺炎治疗药物市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 鲍氏不动桿菌肺炎治疗药物市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • 价格分析
    • 管道分析

第四章鲍氏不动桿菌肺炎治疗药物市场：药物类别估计与趋势分析

  • 全球鲍氏不动桿菌肺炎治疗药物市场：药物类别细分仪表板
  • 全球鲍氏不动桿菌肺炎治疗药物市场：药物类别波动分析
  • 2018-2030年全球鲍氏不动桿菌肺炎治疗药物市场规模及趋势分析（依药物类别）
  • 头孢菌素
  • Fluoroquinolones
  • Glycylcycline
  • 碳青霉烯类
  • β-内酰胺类抗生素
  • 舒巴坦
  • Aminoglycosides
  • 多粘菌素
  • 四环霉素
  • 磺胺类药物
  • 其他的

第五章鲍氏不动桿菌肺炎治疗药物市场：给药途径估算及趋势分析

  • 全球鲍氏不动桿菌肺炎治疗药物市场：给药途径细分仪表板
  • 全球鲍氏不动桿菌肺炎治疗药物市场：给药途径变化分析
  • 2018-2030年全球鲍氏不动桿菌肺炎治疗药物市场规模及趋势分析（依给药途径）
  • 胃肠外的
  • 口服
  • 其他的

第六章鲍氏不动桿菌肺炎治疗药物市场：区域估计与趋势分析

  • 区域市场仪表板
  • 市场规模/预测、趋势分析，2018-2030
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第七章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
    • Pfizer Inc.
    • Merck &Co., Inc.
    • GlaxoSmithKline plc（GSK）
    • AstraZeneca plc
    • Novartis AG
    • Johnson &Johnson
    • Sanofi SA
    • Bayer AG
    • Basilea Pharmaceutica
Product Code: GVR-4-68040-252-2

Acinetobacter Pneumonia Therapeutics Market Growth & Trends:

The global acinetobacter pneumonia therapeutics market size is expected to reach USD 470.96 million by 2030, registering a CAGR of 6.70% from 2024 to 2030, according to a new report by Grand View Research, Inc. Several factors are responsible for driving market growth including a high incidence of acinetobacter infections, rising antibiotic resistance, extensive R&D, and favorable government initiatives & funding, and rising drug resistance. Acinetobacter baumannii is a major pathogen responsible for causing hospital-acquired infections in hospitalized patients. The pathogen causes ventilator-associated pneumonia and bloodstream infection. This strain of microorganisms has been reported to be multidrug-resistant and can spread extremely fast.

The treatment of this microorganism can be challenging and is hampered due to the multidrug resistance of the Acinetobacter baumannii. Combination therapy is the most widely used treatment for these kinds of infections. The first line of treatment for acinetobacter pneumonia includes drug classes, such as B-lactam antibiotics, cephalosporins, carbapenem, fluoroquinolone, sulbactam, and sulfonamide. The therapeutics are used in monotherapy or as part of combination therapy depending on the severity of illness. In case the first-line treatment is not effective, second-line antibiotics are administered, which include drug classes, such as aminoglycoside, polymyxins, tetracycline, and glycylcycline. These drugs are considered second-line due to their adverse effects.

Acinetobacter Pneumonia Therapeutics Market Report Highlights:

  • The cephalosporins drug class segment accounted for the largest revenue share in 2023. Ceftazidime is used as a first-line treatment; cefiderocol is used as second-linene treatment for the disease
  • In addition, the newly launched Xacduro under the sulbactam segment is expected to grow at a significant CAGR during the forecast period
  • Based on the route of administration, the parenteral segment accounted for the largest revenue share in 2023. The rapid and direct delivery of antibiotics via the IV route ensures rapid absorption and efficacy and makes it the preferred method for treating severe infections
  • Xacduro (sulbactam for injection; durlobactam for injection), polymyxins (colistin), carbapenems, and aminoglycosides are some of the drugs administered parenterally for the treatment of acinetobacter pneumonia
  • In 2023, North America dominated with a share of 37.31% owing to the advanced healthcare infrastructure, high awareness levels, and extensive research activities for clinical trials
  • The region has a high prevalence of acinetobacter pneumonia along with high awareness about disease diagnosis and treatment

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Route of Administration
  • 1.3. Regional scope
  • 1.4. Estimates and forecasts timeline
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased database
    • 1.6.2. GVR's internal database
    • 1.6.3. Secondary sources
    • 1.6.4. Primary research
    • 1.6.5. Details of primary research
      • 1.6.5.1. Data for primary interviews in North America
      • 1.6.5.2. Data for primary interviews in Europe
      • 1.6.5.3. Data for primary interviews in Asia Pacific
      • 1.6.5.4. Data for primary interviews in Latin America
      • 1.6.5.5. Data for Primary interviews in MEA
  • 1.7. Information or Data Analysis
    • 1.7.1. Data analysis models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity flow analysis (Model 1)
    • 1.9.2. Approach 1: Commodity flow approach
    • 1.9.3. Volume price analysis (Model 2)
    • 1.9.4. Approach 2: Volume price analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Primary Sources
  • 1.12. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug class outlook
    • 2.2.2. Route of administration outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Acinetobacter Pneumonia Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing incidence of Acinetobacter infections
      • 3.2.1.2. Increasing prevalence of antibiotic resistance
      • 3.2.1.3. Increasing research & development and fundings
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Side effects and adverse reactions
      • 3.2.2.2. High cost of drug development
  • 3.3. Acinetobacter Pneumonia Therapeutics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis
    • 3.3.4. Pipeline Analysis

Chapter 4. Acinetobacter Pneumonia Therapeutics Market: Drug Class Estimates & Trend Analysis

  • 4.1. Global Acinetobacter Pneumonia Therapeutics Market: Drug Class Segment Dashboard
  • 4.2. Global Acinetobacter Pneumonia Therapeutics Market: Drug Class Movement Analysis
  • 4.3. Global Acinetobacter Pneumonia Therapeutics Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 4.4. Cephalosporins
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Fluoroquinolone
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Glycylcycline
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Carbapenem
    • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. B-Lactam antibiotics
    • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. Sulbactam
    • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10. Aminoglycoside
    • 4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.11. Polymyxins
    • 4.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.12. Tetracycline
    • 4.12.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.13. Sulfonamide
    • 4.13.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.14. Other
    • 4.14.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Acinetobacter Pneumonia Therapeutics Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Global Acinetobacter Pneumonia Therapeutics Market: Route of Administration Segment Dashboard
  • 5.2. Global Acinetobacter Pneumonia Therapeutics Market: Route of Administration Movement Analysis
  • 5.3. Global Acinetobacter Pneumonia Therapeutics Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 5.4. Parenteral
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Oral
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Other
    • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Acinetobacter Pneumonia Therapeutics Market: Regional Estimates & Trend Analysis by

  • 6.1. Regional Market Dashboard
  • 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
    • 7.3.4. Pfizer Inc.
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Merck & Co., Inc.
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. GlaxoSmithKline plc (GSK)
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. AstraZeneca plc
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Novartis AG
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Johnson & Johnson
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Sanofi S.A.
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. Bayer AG
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Basilea Pharmaceutica
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives

List of Tables

  • Table 1 List of key distributors and channel partners
  • Table 2 List of key emerging companies'/technology disruptors/innovators
  • Table 3 North America Acinetobacter Pneumonia Therapeutics Market, by country, 2018 - 2030 (USD Million)
  • Table 4 North America Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 5 North America Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 6 U.S. Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 7 U.S. Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 8 Canada Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 9 Canada Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 10 Europe Acinetobacter Pneumonia Therapeutics Market, by country, 2018 - 2030 (USD Million)
  • Table 11 Europe Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 12 Europe Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 13 Germany Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 14 Germany Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 15 UK Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 16 UK Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 17 France Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 18 France Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 19 Italy Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 20 Italy Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million
  • Table 21 Spain Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 22 Spain Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 23 Denmark Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 24 Denmark Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 25 Sweden Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 26 Sweden Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 27 Norway Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 28 Norway Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific Acinetobacter Pneumonia Therapeutics Market, by country, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 32 Japan Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 33 Japan Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 34 China Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 35 China Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 36 India Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 37 India Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 38 Australia Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 39 Australia Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 40 South Korea Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 41 South Korea Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 42 Thailand Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 43 Thailand Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 44 Latin America Acinetobacter Pneumonia Therapeutics Market, by country, 2018 - 2030 (USD Million)
  • Table 45 Latin America Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 46 Latin America Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million
  • Table 47 Brazil Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 48 Brazil Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 49 Mexico Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 50 Mexico Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 51 Argentina Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 52 Argentina Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 53 MEA Acinetobacter Pneumonia Therapeutics Market, by country, 2018 - 2030 (USD Million)
  • Table 54 MEA Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 55 MEA Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 56 South Africa Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 57 South Africa Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 59 Saudi Arabia Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 60 UAE Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 61 UAE Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 62 Kuwait Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 63 Kuwait Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Acinetobacter pneumonia therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Acinetobacter pneumonia therapeutics market snapshot (2023)
  • Fig. 9 Acinetobacter pneumonia therapeutics market: Segment snapshot (2023)
  • Fig. 10 Competitive Insights (2023)
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Acinetobacter Pneumonia Therapeutics Market driver impact
  • Fig. 15 Acinetobacter Pneumonia Therapeutics Market restraint impact
  • Fig. 16 Porter's Five Forces Analysis
  • Fig. 17 SWOT Analysis, By Factor (Political & legal Economic and technological)
  • Fig. 18 Strategic alliance analysis
  • Fig. 19 Recent developments & impact analysis, by key market participants
  • Fig. 20 Key company market share analysis, 2023
  • Fig. 21 Company market position analysis
  • Fig. 22 Definition and scope, by drug class
  • Fig. 23 Drug class market share analysis, 2023 & 2030
  • Fig. 24 Segment dashboard
  • Fig. 25 Global Acinetobacter Pneumonia Therapeutics Market, by drug class, 2018 - 2030 (USD Million)
  • Fig. 26 Cephalosporins market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 27 Nonsteroidal Anti-inflammatory Drugs market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 28 Naproxen market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 29 Fluoroquinolone market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 30 Glycylcycline market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 31 Carbapenem market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 32 B-Lactam antibiotics market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 33 Sulbactam market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 34 Aminoglycoside market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 35 Polymyxins market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 36 Other NSAIDs market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 37 Tetracycline market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 38 Sulfonamide market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 39 Others market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 40 Definition and scope, by Route of Administration
  • Fig. 41 Anatomy market share analysis, 2023 & 2030
  • Fig. 42 Segment dashboard
  • Fig. 43 Global Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Fig. 44 Parenteral market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 45 Oral market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 46 Other route market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 47 North America market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 48 U.S. market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 49 Canada market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 50 Europe market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 51 UK market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 52 Germany market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 53 Spain market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 54 France market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 55 Italy market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 56 Sweden market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 57 Denmark market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 58 Norway market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 59 Asia Pacific market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 60 China market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 61 Japan market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 62 India market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 63 Australia market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 64 South Korea market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 65 Thailand market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 66 Latin America market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 67 Brazil market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 68 Mexico market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 69 Argentina market size, & forecasts and trend analysis, 2018 to 2030 (USD Million))
  • Fig. 70 Middle East and Africa market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 71 South Africa market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 72 Saudi Arabia market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 73 UAE market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 74 Kuwait market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)